{
    "clinical_study": {
        "@rank": "31640", 
        "acronym": "LIVE", 
        "arm_group": [
            {
                "arm_group_label": "100 mg IV", 
                "arm_group_type": "Other", 
                "description": "100 mg IV lacosamide infused over 30 minutes"
            }, 
            {
                "arm_group_label": "200 mg IV", 
                "arm_group_type": "Other", 
                "description": "200 mg IV lacosamide infused over 30 minutes"
            }, 
            {
                "arm_group_label": "400 mg IV", 
                "arm_group_type": "Other", 
                "description": "400 mg IV lacosamide infused over 30 minutes"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a\n      new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram)\n      rhythms (or brain rhythms) in subjects with focal seizures and the tolerability of those\n      doses by patients.  In addition, this study will assess the effect of IV lacosamide on EKG\n      (electrocardiogram), a test which checks for problems with the electrical activity of the\n      heart."
        }, 
        "brief_title": "Lacosamide IV and EEG/EKG (LIVE) Study", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Focal Epilepsy", 
        "condition_browse": {
            "mesh_term": [
                "Epilepsy", 
                "Epilepsies, Partial"
            ]
        }, 
        "detailed_description": {
            "textblock": "The impact of antiepileptic drugs on the EEG can vary from marked to none. A small number of\n      AEDs also affect the EKG. Lacosamide is a new AED that selectively enhances slow\n      inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable\n      neuronal membranes and inhibition of repetitive neuronal firing. Information is lacking\n      about the effect of lacosamide on brain and heart rhythms."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is informed and given ample time and opportunity to think about her/his\n             participation and has given her/his written informed consent.\n\n          2. Adult patients 18-65 years\n\n          3. Diagnosis of focal epilepsy\n\n          4. Continuous EEG and video monitoring\n\n          5. Continuous EKG\n\n          6. Active EEG showing frequent spikes, electrographic or clinical seizures\n\n        Exclusion Criteria:\n\n          1. Subject has no IV access.\n\n          2. Subject is hemodynamically unstable.\n\n          3. Previous use of Lacosamide\n\n          4. Primary generalized epilepsy\n\n          5. Non-epileptic seizures\n\n          6. No significant cardiac, renal or hepatic disease\n\n          7. No cardiac arrhythmias including heart block\n\n          8. Subject is a pregnant or lactating woman."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01724918", 
            "org_study_id": "LIVE 001"
        }, 
        "intervention": {
            "arm_group_label": [
                "100 mg IV", 
                "200 mg IV", 
                "400 mg IV"
            ], 
            "intervention_name": "Lacosamide", 
            "intervention_type": "Drug", 
            "other_name": "Vimpat"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "IV lacosamide", 
            "focal epilepsy", 
            "EEG", 
            "EKG"
        ], 
        "lastchanged_date": "April 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 2T9"
                    }, 
                    "name": "Foothills Medical Center"
                }, 
                "investigator": {
                    "last_name": "Neelan Pillay, MB, ChB", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 5A5"
                    }, 
                    "name": "London Health Sciences Centre"
                }, 
                "investigator": {
                    "last_name": "Richard S McLachlan, MD, FRCPC", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saskatoon", 
                        "country": "Canada", 
                        "state": "Saskatchewan", 
                        "zip": "S7N 0W8"
                    }, 
                    "name": "Royal University Hospital"
                }, 
                "investigator": {
                    "last_name": "Jose F Tellez-Zenteno, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "3", 
        "official_title": "Lacosamide IV and EEG/EKG (LIVE) Study", 
        "other_outcome": {
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 4 hours after start of infusion"
        }, 
        "overall_contact": {
            "email": "rsmcl@uwo.ca", 
            "last_name": "Richard McLachlan, MD, FRCPC", 
            "phone": "519-663-3293"
        }, 
        "overall_contact_backup": {
            "email": "suzan.brown@lhsc.on.ca", 
            "last_name": "Suzan Brown, BA", 
            "phone": "519-685-8500", 
            "phone_ext": "32870"
        }, 
        "overall_official": {
            "affiliation": "London Health Sciences Centre, University Campus", 
            "last_name": "Richard McLachlan, MD, FRCPC", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in the number of interictal spikes", 
            "safety_issue": "No", 
            "time_frame": "One hour before and after drug"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01724918"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Lawson Health Research Institute", 
            "investigator_full_name": "Rick McLachlan", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in frequency and quantity of background EEG rhythms", 
                "safety_issue": "No", 
                "time_frame": "One hour before and after drug"
            }, 
            {
                "measure": "Change in EKG (QT, PR interval and heart rhythm)", 
                "safety_issue": "Yes", 
                "time_frame": "One hour before and after drug"
            }
        ], 
        "source": "Lawson Health Research Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "UCB Pharma GmbH", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Lawson Health Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "July 2013"
    }
}